Impact of P53 and SIRT1 in Type 2 Diabetes
Recruiting
Phase 3
Interventional Study
DM
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 90 (estimated)
- Sponsor
- Sherief Abd-Elsalam · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Investigating the impact of p53 and SIRT1 in the development of type 2 DM
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Prediabetic subjects.
Exclusion Criteria:
* Confirmed diabetes.
* Hepatic or renal impairment.
Contacts